Multiple Myeloma/Plasma Cell Dyscrasia

University of Michigan Rogel Cancer Center researcher Arul Chinnaiyan, M.D., Ph.D., has received a $5 million grant from the J.C. Kennedy Foundation to conduct laboratory tests of a potential drug candidate targeting a master regulator that controls the majority of genes involved in the most challenging type of prostate cancer.

By combining data from MRI scans and clinical tests, University of Michigan Rogel Cancer Center researcher Chuan Zhou, Ph.D., will develop a decision support tool to tailor treatment for individual patients with multiple myeloma. It’s a cancer that’s considered incurable, with survival ranging from less than a year to more than a decade, depending on the extent and aggressiveness of the tumors.

Arul Chinnaiyan, M.D., Ph.D., was one of several Rogel researchers to present at the American Association for Cancer Research 2024 Annual Meeting.

Patients with relapsed multiple myeloma are resistant to commonly used treatments. Researchers are one step closer to understanding the genetic reason why.

The awards recognize faculty members’ outstanding clinical research and promising future in oncology.